Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 390

1.

CSF and brain structural imaging markers of the Alzheimer's pathological cascade.

Yang X, Tan MZ, Qiu A.

PLoS One. 2012;7(12):e47406. doi: 10.1371/journal.pone.0047406. Epub 2012 Dec 19.

2.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

3.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
4.

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.

Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ.

Neurobiol Aging. 2011 Dec;32(12):2322.e19-27. doi: 10.1016/j.neurobiolaging.2010.05.023. Epub 2010 Jul 1.

5.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

6.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
7.

Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors.

Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, Zhu W, Park M, Jiang T, Jin JS; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2011;6(7):e21896. doi: 10.1371/journal.pone.0021896. Epub 2011 Jul 21.

8.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

9.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

10.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

11.

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hårdemark HG, Frisoni GB.

J Alzheimers Dis. 2011;26 Suppl 3:159-99. doi: 10.3233/JAD-2011-0043. Review.

PMID:
21971460
12.

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.

Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2013 Oct 11;5:55. doi: 10.3389/fnagi.2013.00055. eCollection 2013.

13.

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.

Neurobiol Aging. 2012 Oct;33(10):2272-81. doi: 10.1016/j.neurobiolaging.2011.12.017. Epub 2012 Jan 20.

PMID:
22264648
14.

Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives.

Lampert EJ, Roy Choudhury K, Hostage CA, Petrella JR, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

PLoS One. 2013 Apr 17;8(4):e60747. doi: 10.1371/journal.pone.0060747. Print 2013.

15.

Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.

Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, Jagust W, Jack C, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol Commun. 2014 Mar 6;2:26. doi: 10.1186/2051-5960-2-26.

16.

Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion.

Westman E, Muehlboeck JS, Simmons A.

Neuroimage. 2012 Aug 1;62(1):229-38. doi: 10.1016/j.neuroimage.2012.04.056. Epub 2012 May 3.

PMID:
22580170
17.

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

J Neurosci. 2010 Feb 10;30(6):2088-101. doi: 10.1523/JNEUROSCI.3785-09.2010.

18.

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O.

PLoS One. 2012;7(6):e38639. doi: 10.1371/journal.pone.0038639. Epub 2012 Jun 22.

19.

An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients.

Aksu Y, Miller DJ, Kesidis G, Bigler DC, Yang QX.

PLoS One. 2011;6(10):e25074. doi: 10.1371/journal.pone.0025074. Epub 2011 Oct 12.

20.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk